In addition, soluble BTLA (sBTLA) in plasma is significantly associated with the risk of death in patients with clear cell renal cell cancer, suggesting that sBTLA has a similar role to membranous BTLA in inhibiting T cell response (52). This evidence concerns the gene BTLA and clear cell renal carcinoma.